Emerging therapies for overactive bladder: preclinical, phase I and phase II studies

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology. 2003 Jan;61:(1):37–49.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20:(6):327–336.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Liu SP, Lee KS, et al. Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study. Low Urin Tract Symptoms. 2019 Jan;11:(1):48–55.
   PubMed Web of Science ®Google Scholar
• Milsom I, Kaplan SA, Coyne KS, et al. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012 Jul;80:(1):90–96.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011 May;77:(5):1081–1087.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Wein A, Nicholson S, et al. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014 Feb;20:(2):130–140.
   PubMed Web of Science ®Google Scholar
• Andersson KE. Emerging drugs for the treatment of bladder storage dysfunction. Expert Opin Emerg Drugs. 2022 Sep;27(3):277–287. doi: 10.1080/14728214.2022.2113057.
   PubMed Web of Science ®Google Scholar
• Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016 Oct;7(5):204–216. doi: 10.1177/2042098616659412
   PubMed Web of Science ®Google Scholar
• Chapple CR, Amarenco G, López Aramburu MA, et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013 Nov;32:(8):1116–1122.
   PubMed Web of Science ®Google Scholar
• Zoqlam R, Lazauskaite S, Glickman S, et al. Emerging molecular mechanisms and genetic targets for developing novel therapeutic strategies for treating bladder diseases. Eur J Pharm Sci. 2022 Jun 1;173:106167. doi: 10.1016/j.ejps.2022.106167
   PubMed Web of Science ®Google Scholar
• Peyronnet B, Mironska E, Chapple C, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019 Jun;75(6):988–1000. doi: 10.1016/j.eururo.2019.02.038.
   PubMed Web of Science ®Google Scholar
• Bradley CS, Nygaard IE, Hillis SL, et al. Longitudinal associations between mental health conditions and overactive bladder in women veterans. Am J Obstet Gynecol. 2017 Oct;217:(4):e430.1–e430.8.
   Web of Science ®Google Scholar
• Yoshida M, Homma Y, Inadome A, et al. Age-related changes in cholinergic and purinergic neurotransmission in human isolated bladder smooth muscles. Exp Gerontol. 2001 Jan;36:(1):99–109.
   PubMed Web of Science ®Google Scholar
• McCarthy CJ, Ikeda Y, Skennerton D, et al. Characterisation of nerve-mediated ATP release from bladder detrusor muscle and its pathological implications. Br J Pharmacol. 2019 Dec;176:(24):4720–4730.
   PubMed Web of Science ®Google Scholar
• Fusco F, Creta M, De Nunzio C, et al. Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans. BMC Urol. 2018 Mar 9;18(1):15. doi: 10.1186/s12894-018-0329-4
   PubMedGoogle Scholar
• Jiang YH, Lee CL, Kuo HC. Urothelial dysfunction, Suburothelial Inflammation and altered sensory protein expression in men with bladder outlet obstruction and various bladder dysfunctions: correlation with Urodynamics. J Urol. 2016 Sep;196(3):831–837. doi: 10.1016/j.juro.2016.02.2958
   PubMed Web of Science ®Google Scholar
• Chess-Williams R, Sellers DJ. Pathophysiological mechanisms involved in overactive Bladder/Detrusor overactivity. Curr Bladder Dysfunct Rep. 2023 Jun 01;18(2):79–88. doi: 10.1007/s11884-023-00690-x.
   Web of Science ®Google Scholar
• Meng E, Lin WY, Lee WC, et al. Pathophysiology of overactive bladder. Low Urin Tract Symptoms. 2012 Mar;4:(Suppl 1):48–55.
   PubMedGoogle Scholar
• Hsu LN, Hu JC, Chen PY, et al. Metabolic syndrome and overactive bladder syndrome may share common pathophysiologies. Biomedicines. 2022 Aug 12;10(8):1957. doi: 10.3390/biomedicines10081957
   PubMed Web of Science ®Google Scholar
• Velasquez Flores M, Mossa AH, Cammisotto P, et al. Succinate decreases bladder function in a rat model associated with metabolic syndrome. Neurourol Urodyn. 2018 Jun;37:(5):1549–1558.
   PubMed Web of Science ®Google Scholar
• Leiria LO, Sollon C, Báu FR, et al. Insulin relaxes bladder via PI3K/AKT/eNOS pathway activation in mucosa: unfolded protein response-dependent insulin resistance as a cause of obesity-associated overactive bladder. J Physiol. 2013 May 1;591(9):2259–2273. doi: 10.1113/jphysiol.2013.251843
   PubMed Web of Science ®Google Scholar
• He Q, Wang Z, Liu G, et al. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis. 2016 Mar;19:(1):7–13.
   PubMed Web of Science ®Google Scholar
• Wu YH, Chueh KS, Chuang SM, et al. Bladder hyperactivity induced by oxidative stress and bladder ischemia: a review of treatment strategies with antioxidants. Int J Mol Sci. 2021 Jun 2;22(11):6014. doi: 10.3390/ijms22116014
   PubMed Web of Science ®Google Scholar
• Camões J, Coelho A, Castro-Diaz D, et al. Lower urinary tract symptoms and aging: the impact of chronic bladder ischemia on overactive bladder syndrome. Urol Int. 2015;95(4):373–379. doi: 10.1159/000437336
   PubMed Web of Science ®Google Scholar
• Tyagi P, Barclay D, Zamora R, et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol. 2010 Sep;42:(3):629–635.
   PubMed Web of Science ®Google Scholar
• Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004 Jul;84(3):935–986. doi: 10.1152/physrev.00038.2003
   PubMed Web of Science ®Google Scholar
• Petkov GV. Central role of the BK channel in urinary bladder smooth muscle physiology and pathophysiology. Am J Physiol Regul Integr Comp Physiol. 2014 Sep 15;307(6):R571–84. doi: 10.1152/ajpregu.00142.2014
   PubMed Web of Science ®Google Scholar
• Fry CH, McCloskey KD. Purinergic signalling in the urinary bladder - when function becomes dysfunction. Auton Neurosci. 2021 Nov;235:102852. doi: 10.1016/j.autneu.2021.102852
   PubMed Web of Science ®Google Scholar
• Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006 Feb;147(Suppl 2):S80–7. doi: 10.1038/sj.bjp.0706560
   PubMedGoogle Scholar
• Ehlert FJ, Griffin MT, Abe DM, et al. The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J Pharmacol Exp Ther. 2005 Apr;313:(1):368–378.
   PubMed Web of Science ®Google Scholar
• Braverman AS, Kohn IJ, Luthin GR, et al. Prejunctional M1 facilitory and M2 inhibitory muscarinic receptors mediate rat bladder contractility. Am J Physiol. 1998 Feb;274:(2):R517–23.
   PubMedGoogle Scholar
• Braverman AS, Ruggieri MR Sr. Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. Am J Physiol Regul Integr Comp Physiol. 2003 Sep;285(3):R701–8. doi: 10.1152/ajpregu.00009.2003
   PubMed Web of Science ®Google Scholar
• Pontari MA, Braverman AS, Ruggieri MR Sr. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. American Journal Of Physiology-Regulatory, Integrative And Comparative Physiology. 2004 May;286(5):R874–80. doi: 10.1152/ajpregu.00391.2003
   PubMed Web of Science ®Google Scholar
• Braverman AS, Luthin GR, Ruggieri MR. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol. 1998 Nov;275(5):R1654–60. doi: 10.1152/ajpregu.1998.275.5.R1654
   PubMedGoogle Scholar
• Bylund DB, Eikenberg DC, Hieble JP, et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev. 1994 Jun;46(2):121–136.
   PubMed Web of Science ®Google Scholar
• Cheng X, Ji Z, Tsalkova T, et al. Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim Biophys Sin (Shanghai). 2008 Jul;40:(7):651–662.
   PubMed Web of Science ®Google Scholar
• Ferro A. Beta-adrenoceptors and potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 2006 Jun;373(3):183–185. doi: 10.1007/s00210-006-0065-2
   PubMed Web of Science ®Google Scholar
• Okeke K, Gravas S, Michel MC. Do β(3)-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release? Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F859–f861. doi: 10.1152/ajprenal.00215.2017
   PubMed Web of Science ®Google Scholar
• Igawa Y, Aizawa N, Michel MC. β(3) -adrenoceptors in the normal and diseased urinary bladder-what are the open questions? Br J Pharmacol. 2019 Jul;176(14):2525–2538. doi: 10.1111/bph.14658
   PubMed Web of Science ®Google Scholar
• Guan NN, Gustafsson LE, Svennersten K. Inhibitory effects of urothelium-related factors. Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):220–224. doi: 10.1111/bcpt.12785
   PubMed Web of Science ®Google Scholar
• Sellers D, Chess-Williams R, Michel MC. Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2018 Jul;391(7):675–694. doi: 10.1007/s00210-018-1510-8
   PubMed Web of Science ®Google Scholar
• Otsuka A, Kawasaki H, Matsumoto R, et al. Expression of β-adrenoceptor subtypes in urothelium, interstitial cells and detrusor of the human urinary bladder. Low Urin Tract Symptoms. 2013 Sep;5:(3):173–180.
   PubMed Web of Science ®Google Scholar
• Andersson KE. Agents in early development for treatment of bladder dysfunction - promise of drugs acting at TRP channels? Expert Opin Investig Drugs. 2019 Sep;28(9):749–755. doi: 10.1080/13543784.2019.1654994
   PubMed Web of Science ®Google Scholar
• Kanai A, Zabbarova I, Oefelein M, et al. Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011. Neurourol Urodyn. 2012 Mar;31:(3):300–308.
   PubMed Web of Science ®Google Scholar
• Coelho A, Antunes-Lopes T, Gillespie J, et al. Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: an immunohistochemical study. Neurourol Urodyn. 2017 Nov;36:(8):1972–1980.
   PubMed Web of Science ®Google Scholar
• Joseph S, Maria SA, Peedicayil J. Drugs Currently undergoing preclinical or clinical trials for the treatment of overactive bladder: a review. Curr Ther Res Clin Exp. 2022;96:100669. doi: 10.1016/j.curtheres.2022.100669
   PubMed Web of Science ®Google Scholar
• George N, Shiny PJ, Miriam J, et al. Inhibitory effect of anticholinergics on the contraction of isolated caprine urinary bladder detrusor muscle. Auton Autacoid Pharmacol. 2010 Jul;30:(3):173–177.
   PubMedGoogle Scholar
• Hicks A, McCafferty GP, Riedel E, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007 Oct;323:(1):202–209.
   PubMed Web of Science ®Google Scholar
• Maruyama I, Tatemichi S, Goi Y, et al. Effects of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther. 2012 Jul;342:(1):163–168.
   PubMed Web of Science ®Google Scholar
• Philyppov IB, Golub AА, Boldyriev OI, et al. Myorelaxant action of fluorine-containing pinacidil analog, flocalin, in bladder smooth muscle is mediated by inhibition of l-type calcium channels rather than activation of KATP channels. Naunyn-Schmiedeberg’s Arch Pharmacol. 2016;389(6):585–592. doi: 10.1007/s00210-016-1228-4
   Google Scholar
• Faruqui AR, Mathai J, George J, et al. Inhibitory effect of nicorandil on the contraction of isolated human urinary bladder detrusor muscle. Methods Find Exp Clin Pharmacol. 2008 Jun;30:(5):363–366.
   PubMedGoogle Scholar
• La Fuente JM, Fernández A, Cuevas P, et al. Stimulation of large-conductance calcium-activated potassium channels inhibits neurogenic contraction of human bladder from patients with urinary symptoms and reverses acetic acid-induced bladder hyperactivity in rats. Eur J Pharmacol. 2014 Jul 15;735:68–76. doi: 10.1016/j.ejphar.2014.03.060
   PubMed Web of Science ®Google Scholar
• Badawi JK, Ding A, Bross S. Inhibitory effects of different ATP-sensitive potassium channel openers on electrically generated and carbachol-induced contractions of porcine and human detrusor muscle. Fundam Clin Pharmacol. 2008 Feb;22(1):75–86. doi: 10.1111/j.1472-8206.2007.00558.x
   PubMed Web of Science ®Google Scholar
• Edwards G, Henshaw M, Miller M, et al. Comparison of the effects of several potassium-channel openers on rat bladder and rat portal vein in vitro. Br J Pharmacol. 1991 Mar;102:(3):679–686.
   PubMed Web of Science ®Google Scholar
• Mora TC, Suarez-Kurtz G. Effects of NS1608, a BK(Ca) channel agonist, on the contractility of guinea-pig urinary bladder in vitro. Br J Pharmacol. 2005;144(5):636–641. doi: 10.1038/sj.bjp.0706034
   PubMed Web of Science ®Google Scholar
• Siemer C, Bushfield M, Newgreen D, et al. Effects of NS1608 on MaxiK channels in smooth muscle cells from urinary bladder. J Membr Biol. 2000 Jan 1;173(1):57–66. doi: 10.1007/s002320001007
   PubMed Web of Science ®Google Scholar
• Li J, Liu T, Li N, et al. SKA-31-induced activation of small-conductance calcium-activated potassium channels decreased modulation of detrusor smooth muscle function in a rat model of obesity. J Bioenerg Biomembr. 2022 Jun;54:(3):135–144.
   PubMed Web of Science ®Google Scholar
• Soder RP, Parajuli SP, Hristov KL, et al. SK channel-selective opening by SKA-31 induces hyperpolarization and decreases contractility in human urinary bladder smooth muscle. Am J Physiol Regul Integr Comp Physiol. 2013 Jan 15;304(2):R155–63. doi: 10.1152/ajpregu.00363.2012
   PubMed Web of Science ®Google Scholar
• Takagi H, Hashitani H. Effects of K(+) channel openers on spontaneous action potentials in detrusor smooth muscle of the guinea-pig urinary bladder. Eur J Pharmacol. 2016 Oct 15;789:179–186. doi: 10.1016/j.ejphar.2016.07.041
   PubMed Web of Science ®Google Scholar
• Lee K, Isogai A, Antoh M, et al. Role of K(+) channels in regulating spontaneous activity in the muscularis mucosae of guinea pig bladder. Eur J Pharmacol. 2018 Jan 5;818:30–37. doi: 10.1016/j.ejphar.2017.10.024
   PubMed Web of Science ®Google Scholar
• Parajuli SP, Hristov KL, Soder RP, et al. NS309 decreases rat detrusor smooth muscle membrane potential and phasic contractions by activating SK3 channels. Br J Pharmacol. 2013 Apr;168:(7):1611–1625.
   PubMed Web of Science ®Google Scholar
• Lee H, Koh BH, Peri LE, et al. Premature contractions of the bladder are suppressed by interactions between TRPV4 and SK3 channels in murine detrusor PDGFRα(+) cells. Sci Rep. 2017 Sep 25;7(1):12245. doi: 10.1038/s41598-017-12561-7
   PubMedGoogle Scholar
• Isogai A, Lee K, Mitsui R, et al. Functional coupling of TRPV4 channels and BK channels in regulating spontaneous contractions of the guinea pig urinary bladder. Pflugers Arch - Eur J Physiol. 2016 Sep;468:(9):1573–1585.
   PubMed Web of Science ®Google Scholar
• Merrill L, Vizzard MA. Intravesical TRPV4 blockade reduces repeated variate stress-induced bladder dysfunction by increasing bladder capacity and decreasing voiding frequency in male rats. Am J Physiol Regul Integr Comp Physiol. 2014 Aug 15;307(4):R471–80. doi: 10.1152/ajpregu.00008.2014
   PubMed Web of Science ®Google Scholar
• Badawi JK, Li H, Langbein S, et al. Inhibitory effects of L- and T-type calcium antagonists on contractions of human detrusor muscle. Eur J Clin Pharmacol. 2006 May;62:(5):347–354.
   PubMed Web of Science ®Google Scholar
• Darblade B, Behr-Roussel D, Oger S, et al. Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: potential therapeutic targets for overactive bladder. Urology. 2006 Aug;68:(2):442–448.
   PubMed Web of Science ®Google Scholar
• Ramos-Filho ACS, Shah A, Augusto TM, et al. Menthol inhibits detrusor contractility independently of TRPM8 activation. PLoS One. 2014;9(11):e111616. doi: 10.1371/journal.pone.0111616
   PubMed Web of Science ®Google Scholar
• Jiang X, Luttrell I, Chitaley K, et al. T- and L-type voltage-gated calcium channels: their role in diabetic bladder dysfunction. Neurourol Urodyn. 2014 Jan;33:(1):147–152.
   PubMed Web of Science ®Google Scholar
• Grundy L, Chess-Williams R, Brierley SM, et al. NKA enhances bladder-afferent mechanosensitivity via urothelial and detrusor activation. Am J Physiol Renal Physiol. 1185 [2018 Oct 1];315(4):F1174–f. doi: 10.1152/ajprenal.00106.2018
   PubMed Web of Science ®Google Scholar
• Hammad FT, Stephen B, Lubbad L, et al. Macroscopic electrical propagation in the guinea pig urinary bladder. Am J Physiol Renal Physiol. 2014 Jul 15;307(2):F172–82. doi: 10.1152/ajprenal.00215.2014
   PubMed Web of Science ®Google Scholar
• Phelps C, Chess-Williams R, Moro C. The dependence of urinary bladder responses on extracellular calcium varies between muscarinic, histamine, 5-HT (serotonin), neurokinin, prostaglandin, and angiotensin receptor activation. Front Physiol. 2022;13:841181. doi: 10.3389/fphys.2022.841181
   PubMed Web of Science ®Google Scholar
• Poley RN, Dosier CR, Speich JE, et al. Stimulated calcium entry and constitutive RhoA kinase activity cause stretch-induced detrusor contraction. Eur J Pharmacol. 2008 Dec 3;599(1–3):137–145. doi: 10.1016/j.ejphar.2008.09.045
   PubMed Web of Science ®Google Scholar
• Smith AC, Hristov KL, Cheng Q, et al. Novel role for the transient potential receptor melastatin 4 channel in guinea pig detrusor smooth muscle physiology. Am J Physiol Cell Physiol. 2013 Mar 1;304(5):C467–77. doi: 10.1152/ajpcell.00169.2012
   PubMed Web of Science ®Google Scholar
• Parajuli SP, Hristov KL, Sullivan MN, et al. Control of urinary bladder smooth muscle excitability by the TRPM4 channel modulator 9-phenanthrol. Channels (Austin). 2013 Nov;7:(6):537–540.
   PubMed Web of Science ®Google Scholar
• Alom F, Matsuyama H, Nagano H, et al. Involvement of transient receptor potential melastatin 4 channels in the resting membrane potential setting and cholinergic contractile responses in mouse detrusor and ileal smooth muscles. J Vet Med Sci. 2019 Feb 19;81(2):217–228. doi: 10.1292/jvms.18-0631
   PubMed Web of Science ®Google Scholar
• Kullmann FA, Beckel JM, McDonnell B, et al. Involvement of TRPM4 in detrusor overactivity following spinal cord transection in mice. Naunyn Schmiedebergs Arch Pharmacol. 2018 Nov;391:(11):1191–1202.
   PubMed Web of Science ®Google Scholar
• Hristov KL, Smith AC, Parajuli SP, et al. Novel regulatory mechanism in human urinary bladder: central role of transient receptor potential melastatin 4 channels in detrusor smooth muscle function. Am J Physiol Cell Physiol. 2016 Apr 1;310(7):C600–11. doi: 10.1152/ajpcell.00270.2015
   PubMed Web of Science ®Google Scholar
• Nakanishi O, Fujimori Y, Aizawa N, et al. KPR-5714, a novel transient receptor potential melastatin 8 antagonist, improves overactive bladder via inhibition of bladder afferent hyperactivity in rats. J Pharmacol Exp Ther. 2020 May;373:(2):239–247.
   PubMed Web of Science ®Google Scholar
• Tatsumiya K, Yamanishi T, Watanabe M, et al. Effects of fasudil, a Rho-kinase inhibitor, on contraction of pig bladder tissues with or without urothelium. Int J Urol. 2009 Dec;16:(12):959–966.
   PubMed Web of Science ®Google Scholar
• Daugherty SL, Beckel JM, Kim KA, et al. TRP channel agonists activate different afferent neuromodulatory mechanisms in Guinea pig urinary bladder [original research]. Front Physiol. 2021 Jun 24;12:12.
   Web of Science ®Google Scholar
• Oger S, Behr-Roussel D, Gorny D, et al. Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Br J Pharmacol. 2010 Jul;160:(5):1135–1143.
   PubMed Web of Science ®Google Scholar
• Chakrabarty B, Ito H, Ximenes M, et al. Influence of sildenafil on the purinergic components of nerve-mediated and urothelial ATP release from the bladder of normal and spinal cord injured mice. Br J Pharmacol. 2019 Jul;176:(13):2227–2237.
   PubMed Web of Science ®Google Scholar
• Bassiouni W, Senbel A, Norel X, et al. Sildenafil corrects the increased contractility of rat detrusor muscle induced by alprostadil in vitro. Pharmacol Rep. 2019 Aug;71:(4):659–668.
   PubMed Web of Science ®Google Scholar
• Dhruva A, Hamsavardhini VK, Kamatham S, et al. Avanafil inhibits the contractility of the isolated caprine detrusor muscle. Int J Appl Basic Med Res. 2019 Oct;9:(4):231–235.
   PubMedGoogle Scholar
• Dong X, Nakagomi H, Miyamoto T, et al. Tadalafil attenuates hypotonicity-induced Ca(2+) influx via TRPV2 and TRPV4 in primary rat bladder urothelial cell cultures. Neurourol Urodyn. 2018 Jun;37:(5):1541–1548.
   PubMed Web of Science ®Google Scholar
• Ding H, Li N, He X, et al. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast. Int Urol Nephrol. 2017 Oct;49:(10):1723–1730.
   PubMed Web of Science ®Google Scholar
• Jezior JR, Brady JD, Rosenstein DI, et al. Dependency of detrusor contractions on calcium sensitization and calcium entry through LOE-908-sensitive channels. Br J Pharmacol. 2001 Sep;134:(1):78–87.
   PubMed Web of Science ®Google Scholar
• Teixeira CE, Jin L, Priviero FB, et al. Comparative pharmacological analysis of Rho-kinase inhibitors and identification of molecular components of Ca2+ sensitization in the rat lower urinary tract. Biochem Pharmacol. 2007 Aug 15;74(4):647–658. doi: 10.1016/j.bcp.2007.06.004
   PubMed Web of Science ®Google Scholar
• Shahab N, Kajioka S, Seki N, et al. Functional role of muscarinic receptor subtypes in calcium sensitization and their contribution to rho-kinase and protein kinase C pathways in contraction of human detrusor smooth muscle. Urology. 2012 May;79:(5):1184.e7–13.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Saito M, Oiwa H, et al. Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress. Neurourol Urodyn. 2014 Mar;33:(3):350–357.
   PubMed Web of Science ®Google Scholar
• Engin S, Kaya Yasar Y, Barut EN, et al. The inhibitory effect of trimetazidine on detrusor contractility - a potential repositioning of trimetazidine for the treatment of overactive bladder. J Pharm Pharmacol. 2022 Jan 5;74(1):94–102. doi: 10.1093/jpp/rgab072
   PubMed Web of Science ®Google Scholar
• Truss MC, Uckert S, Stief CG, et al. Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro. Neurourol Urodyn. 1996;15(1):59–70. doi: 10.1002/(SICI)1520-6777(1996)15:1<59:AID-NAU6>3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Báu FR, Mónica FZ, Priviero FB, et al. Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle. Eur J Pharmacol. 2010 Jul 10;637(1–3):171–177. doi: 10.1016/j.ejphar.2010.04.008
   PubMed Web of Science ®Google Scholar
• Moon A. Influence of nitric oxide signalling pathways on pre‐contracted human detrusor smooth muscle in vitro. BJU Int. 2002;89(9):942–949. doi: 10.1046/j.1464-410X.2002.02795.x
   PubMed Web of Science ®Google Scholar
• Salcedo C, Davalillo S, Cabellos J, et al. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156:(5):807–817.
   PubMed Web of Science ®Google Scholar
• Song M, Kim JH, Lee KS, et al. The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study. Int J Clin Pract. 2015 Feb;69:(2):242–250.
   PubMed Web of Science ®Google Scholar
• SMP-986 phase 2 proof of concept in patients with overactive bladder syndrome (OABS). ClinicalTrials.gov: National Library of Medicine; [2023 Nov 09]. Available from: https://www.clinicaltrials.gov/study/NCT00409539
   Google Scholar
• Lee MJ, Moon JH, Lee HK, et al. Pharmacological characterization of DA-8010, a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland. Eur J Pharmacol. 2019 Jan 15;843:240–250. doi: 10.1016/j.ejphar.2018.11.037
   PubMed Web of Science ®Google Scholar
• Son HS, Oh CY, Choo MS, et al. Efficacy and safety of DA-8010, a Novel M3 Antagonist, in patients with overactive bladder: a randomized, double-blind phase 2 study. Int Neurourol J. 2022 Jun;26:(2):119–128.
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy and safety of DA-8010 in patients with overactive bladder ClinicalTrials.gov: National Library of Medicine; [2024 Sep 01]. Available from: https://clinicaltrials.gov/study/NCT05282069?intr=da-8010&rank=3
   Google Scholar
• Tyagi P, Thomas CA, Yoshimura N, et al. Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder. Int Braz J Urol. 2009 Jan;35:(1):76–83.
   PubMed Web of Science ®Google Scholar
• Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012 Nov;62(5):834–840. doi: 10.1016/j.eururo.2012.05.053
   PubMed Web of Science ®Google Scholar
• Thiagamoorthy G, Giarenis I, Cardozo L. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome. Expert Opin Investig Drugs. 2015;24(10):1299–1306. doi: 10.1517/13543784.2015.1076390
   PubMed Web of Science ®Google Scholar
• Aishima M, Tomoda T, Yunoki T, et al. Actions of ZD0947, a novel ATP-sensitive K+ channel opener, on membrane currents in human detrusor myocytes. Br J Pharmacol. 2006 Nov;149:(5):542–550.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Patroneva A, Raines SR. Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). Eur Urol. 2006 May;49(5):879–886. doi: 10.1016/j.eururo.2006.01.037
   PubMed Web of Science ®Google Scholar
• Seftel AD. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol. 2004 Apr;27(Suppl S1):14–19. doi: 10.1002/clc.4960271305
   Google Scholar
• Dell’atti L. Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients. Eur Rev Med Pharmacol Sci. 2015;19(9):1559–1563.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang F, Yu Z, et al. Efficacy of daily low-dose tadalafil for treating overactive bladder: results of a randomized, double-blind, placebo-controlled trial. Urology. 2017 Feb;100:59–64. doi: 10.1016/j.urology.2016.11.008
   PubMed Web of Science ®Google Scholar
• Management of OAB in female patients. ClinicalTrials.gov: National Library of Medicine; [2024 Sep 1]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT06184334
   Google Scholar
• Rovner E, Chai TC, Jacobs S, et al. Evaluating the safety and potential activity of URO‐902 (hMaxi‐K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non‐neurogenic) overactive bladder syndrome and detrusor overact. Neurourol Urodyn. 2020;39(2):744–753. doi: 10.1002/nau.24272.
   PubMed Web of Science ®Google Scholar
• Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018 Sep;74:(3):324–333.
   PubMed Web of Science ®Google Scholar